CBFB-MYH11, inv(16) by RT-PCR
0092209
 
Ordering Recommendation
Use for detection of CBFB-MYH11 in acute myeloid leukemia (AML).
Mnemonic
INV(16)
Methodology
Reverse Transcription Polymerase Chain Reaction
Performed
Varies
Reported
4-7 days
New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
 
Collect
Lavender (EDTA) or bone marrow (EDTA).  
Specimen Preparation
Transport 5 mL whole blood or 3 mL bone marrow. (Min: 1 mL whole blood or 1 mL bone marrow) Specimens must be received within 48 hours of collection due to lability of RNA.  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Serum or plasma. Frozen or clotted specimens. Specimens collected in anticoagulants other than EDTA. Severely hemolyzed specimens.  
Remarks
 
Stability
Ambient: 1 hour; Refrigerated: 48 hours; Frozen: Unacceptable  
Reference Interval
Interpretive Data
Refer to report.

See Compliance Statement B: www.aruplab.com/CS
Note
CBFB (core binding factor β-chain)-MYH11 (myosin heavy chain 11 gene) fusion transcripts are detected in approximately 10% of de novo acute myelogenous leukemias (AML). One half of these cases belong to AML subtype M4 with abnormal eosinophils (AML-M4Eo). The fusion results from a pericentric inversion on chromosome 16 inv(16)(p13q22) or rarely from the translocation t(16;16)(p13;q22). Based on the breakpoints in the CBFB and MYH11 genes, greater than 95% of analyzed inv(16) cases belong to three types: A (88%), D (5%), and E (5%).
CPT Code(s)
81401
Components
Component Test Code*Component Chart Name
0096364CBFB-MYH11, inv(16) by RT-PCR
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, contact interface support at interface.support@aruplab.com.
Cross References
  • CBFB-MYH11 inv(16) fusion gene
  • CBFB-MYH11 Inversion
  • inv(16)